Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

OBJECTIVE: Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if...

Descripción completa

Detalles Bibliográficos
Autores principales: Burm, Rani, Maravelia, Panagiota, Ahlen, Gustaf, Ciesek, Sandra, Caro Perez, Noelia, Pasetto, Anna, Urban, Stephan, Van Houtte, Freya, Verhoye, Lieven, Wedemeyer, Heiner, Johansson, Magnus, Frelin, Lars, Sällberg, Matti, Meuleman, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176361/
https://www.ncbi.nlm.nih.gov/pubmed/35977815
http://dx.doi.org/10.1136/gutjnl-2022-327216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176361/
https://www.ncbi.nlm.nih.gov/pubmed/35977815
http://dx.doi.org/10.1136/gutjnl-2022-327216

Ejemplares similares